Reader response: Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trial

It is very strange that Traboulsee et al.1 did not publish any MRI data; this does not allow a metanalysis comparison with other trials. The Brave Dreams trial,2 examined patients with relapsing-remitting multiple sclerosis (RRMS) undergoing percutaneous transluminal angioplasty (PTA) for chronic cerebrospinal venous insufficiency and this Canadian study contains a mixed population of RRMS and secondary-progressive multiple sclerosis (SPMS).1 Furthermore, a population with a mean age of 50 years and a disease duration of 17 years isn't an acceptable study group for PTA. Adverse event nausea and gastrointestinal symptoms are in no way attributable to PTA. Why did the authors attribute a symptom of understandable anxiety (agreement to a double-blind surgery) to the PTA?

http://n.neurology.org/content/reader-response-safety-and-efficacy-venoplasty-ms-randomized-double-blind-sham-controlled-0

It is very strange that Traboulsee et al.1 did not publish any MRI data; this does not allow a metanalysis comparison with other trials. The Brave Dreams trial,2 examined patients with relapsing-remitting multiple sclerosis (RRMS) undergoing percutaneous transluminal angioplasty (PTA) for chronic ce...